论文部分内容阅读
目的:评价艾迪联合美洛昔康治疗原发性肝癌的临床疗效。方法:选择无手术指征的肝癌患者46例,随机分为治疗组和对照组各23例,观察近期疗效、生存质量及不良反应。结果:治疗组和对照组总有效率分别为91.3%和60.9%,两组比较差异有显著性(P<0.05);治疗组和对照组痊愈率分别为8.7%和0,两组比较差异无显著性;生存质量改善治疗组高于对照组,但两组比较差异无显著性;不良反应两组差异无显著性。结论:艾迪与美洛昔康联合对肝癌瘤体有明显的抑制作用,证实联用具有协同作用。
Objective: To evaluate the clinical efficacy of Aidi combined with meloxicam in the treatment of primary liver cancer. Methods: Forty-six patients with hepatocellular carcinoma without surgical indications were randomly divided into treatment group (23 cases) and control group (23 cases). The curative effect, quality of life and adverse reactions were observed. Results: The total effective rates of the treatment group and the control group were 91.3% and 60.9%, respectively, with significant difference between the two groups (P <0.05). The cure rates of the treatment group and the control group were 8.7% and 0 respectively, with no difference between the two groups Significant; quality of life improvement treatment group than the control group, but no significant difference between the two groups; adverse reaction was no significant difference between the two groups. Conclusion: Combination of Eddie and meloxicam significantly inhibits the hepatocellular carcinoma, confirming synergistic effect.